Wild Landscape

HOME

 
Thanks for stopping by. Douglas Toal, PhD, is a clinical scientist with over 25 years of experience in translational research, clinical laboratory operations and diagnostic assay development. He has worked alongside other scientist to pioneer the clinical application of metabolomics for the screening of inborn errors of metabolism and rare disease. Additionally, his teams have developed and validated small molecule assays for conditions like prediabetes and chronic kidney disease. In the area of cell biology and genomics, Dr. Toal has led efforts to introduce innovative clinical diagnostic assays for the identification of Alzheimer's disease, hospital-acquired infections, and other serious infectious diseases. Dr. Toal completed his doctorate in the microbiology at the University of Oklahoma where he studied intercellular communication in soil bacteria. He completed post-doctoral fellowship training at the Mayo Clinic in Rochester, Minnesota. He is board certified in Medical and Public Health Microbiology by the American Board of Medical Microbiology.  Selected publications are listed below

Hi There!

Q4dsRFV_edited.jpg

SELECT PUBLICATIONS

Clinical Metabolomics for Inborn Errors of Metabolism

Lisa Ford, Matthew Mitchell, Jacob Wulff, Annie Evans, Adam Kennedy, Sarah Elsea, Bryan Wittmann, Douglas Toal

Advances in Clinical Chemistry, 2022: 107, 79-138

Metabolism is a highly regulated process that provides nutrients to cells and essential building blocks for the synthesis of protein, DNA and other macromolecules. In healthy biological systems, metabolism maintains a steady state in which the concentrations of metabolites are relatively constant yet are subject to metabolic demands and environmental stimuli...

Assessment of the Effects of Repeated Freeze Thawing and Extended Bench Top Processing of Plasma Samples Using Untargeted Metabolomics

 

Kelli Goodman, Matthew Mitchell, Anne M. Evans, Luke A. D. Miller, Lisa Ford, Bran Wittmann, Adam D. Kennedy, and Douglas Toal

Metabolomics 2021, 17,31

Clinical metabolomics has utility as a screen for inborn errors of metabolism (IEM) and variant classification in patients with rare disease. It is important to understand and characterize preanalytical factors that influence assay performance during patient sample testing...

Global Biochemical Analysis of Plasma, Serum, and Whole Blood Collected Using Various Anticoagulant Additives

 

Adam D. Kennedy, Lisa Ford, Bryan Wittmann, Jesse Conner, Jacob Wulff, Matthew Mitchell, Anne M Evans, Douglas R. Toal

PLoS One, 2021 8;16(4)

Analysis of blood for the evaluation of clinically relevant biomarkers requires precise collection and sample handling by phlebotomists and laboratory staff. An important consideration for the clinical application of metabolomics are the different anticoagulants utilized for sample collection. Most studies that have characterized differences in metabolite levels in various blood collection tubes have focused on single analytes.

Precision of a Clinical Metabolomics Profiling Platform for Use in the Identification of Inborn Errors of Metabolism

Lisa Ford, Adam D Kennedy, Kelli D Goodman, Kirk L Pappan, Anne M Evans, Luke A D Miller, Jacob E Wulff, Bobby R Wiggs, III, John J Lennon, Sarah Elsea, Douglas R Toal

The Journal of Applied Laboratory Medicine, Volume 5, Issue 2, March 2020, Pages 342–356

The application of whole-exome sequencing for the diagnosis of genetic disease has paved the way for systems-based approaches in the clinical laboratory. Here, we describe a clinical metabolomics method for the screening of metabolic diseases through the analysis of a multi-pronged mass spectrometry platform. By simultaneously measuring hundreds of metabolites in a single sample, clinical metabolomics offers a comprehensive approach to identify metabolic perturbations across multiple biochemical pathways.

Validation of a Metabolite Panel for a More Accurate Estimation of Glomerular Filtration Rate Using Quantitative LC-MS/MS

Tiffany A FreedJosef CoreshLesley A InkerDouglas R ToalRegis PerichonJingsha ChenKelli D GoodmanQibo ZhangJessie K ConnerDeirdre M HauserKate E T VroomMaria L OyaskiJacob E WulffGudný EiríksdóttirVilmundur GudnasonVicente E TorresLisa A FordAndrew S Levey

Clinical Chemistry, 2019 Mar;65(3):406-418

Clinical practice guidelines recommend estimation of glomerular filtration rate (eGFR) using validated equations based on serum creatinine (eGFRcr), cystatin C (eGFRcys), or both (eGFRcr-cys). However, when compared with the measured GFR (mGFR), only eGFRcr-cys meets recommended performance standards. Our goal was to develop a more accurate eGFR method using a panel of metabolites without creatinine, cystatin C, or demographic variables.

Metabolomics in the Clinic: A Review of the Shared and Unique Features of Untargeted Metabolomics for Clinical Research and Clinical Testing

Adam D. Kennedy, Bryan M. Wittmann, Anne M. Evans, Luke A.D. Miller, Douglas R. Toal, Shaun Lonergan, Sarah H. Elsea, Kirk L. Pappan

Journal of Mass Spectrometry, 2018; 53:1143–1154

Metabolomics is the untargeted measurement of the metabolome, which is composed of the complement of small molecules detected in a biological sample. As such, metabolomic analysis produces a global biochemical phenotype. It is a technology that has been utilized in the research setting for over a decade. The metabolome is directly linked to and is influenced by genetics, epigenetics, environmental factors, and the microbiome—all of which affect health...

Identification of an Endogenous Organosulfur Metabolite by Interpretation of Mass Spectrometric Data

 

Qibo Zhang*, Lisa A. Ford, Anne M. Evans, and Douglas R. Toal
Organic Letters, 2018; 20, 7:2100-2103

The chemical structure of x11564, a new endogenous organosulfur metabolite, was elucidated by de novo interpretation of mass spectrometric data. The structure was confirmed by comparison to a synthetic standard. Metabolite x11564 is structurally related to intermediates in the methionine salvage pathway...

Structure Elucidation of Metabolite x17299 by Interpretation of Mass Spectrometric Data

Qibo Zhang, Lisa A. Ford, Anne M. Evans, Douglas R. Toal 

Metabolomics, June 2017; 13,92

A major bottleneck in metabolomic studies is metabolite identification from accurate mass spectrometric data. Metabolite x17299 was identified in plasma as an unknown in a metabolomic study using a compound-centric approach where the associated ion features of the compound were used to determine the true molecular mass.

LC-MS/MS Method for Quantitation of Seven Biomarkers in Human Plasma for the Assessment of Insulin Resistance and Impaired Glucose Tolerance

Qibo ZhangLisa A FordKelli D GoodmanTiffany A FreedDeirdre M HauserJessie K ConnerKate E T Vroom, Douglas R Toal

Journal of Chromatography B, 2016; 1038:101-108

Early detection of insulin resistance (IR) and/or impaired glucose tolerance (IGT) is crucial for delaying and preventing the progression toward type 2 diabetes. We recently developed and validated a straightforward metabolite-based test for the assessment of IR and IGT in a single LC–MS/MS method...

Multidrug-Resistant Organism Colonization in a High-Risk Pediatric Patient Population

 

Xiaoyan Song, Douglas Toal, Terry Walker, Evelio D. Perez-Albuerne, Joseph M. Campos, and Roberta L. DeBiasi

Infection Control & Hospital Epidemiology, 2016; 37(5), 615-616​

Multidrug-resistant organisms (MDROs) present substantial clinical and financial burdens to patients and hospitals. In pediatric patients undergoing cancer or hematopoietic stem cell treatment, information is needed to characterize...

Analytical Performance of Multiplexed Screening Test for 10 Antibiotic Resistance Genes from Perianal Swab Samples

G Terrance WalkerTony J RockweilerRossio K KerseyKelly L FryeSusan R MitchnerDouglas R ToalJulia Quan

Clinical Chemistry, 2016; 62(2):353-359

Multiantibiotic-resistant bacteria pose a threat to patients and place an economic burden on health care systems. Carbapenem-resistant bacilli and extended-spectrum β-lactamase (ESBL) producers drive the need to screen infected and colonized patients for patient management and infection control...

Laboratory Diagnosis of Central Nervous System Infections with Herpes Simplex Virus by PCR Performed with Cerebrospinal Fluid Specimens

 

P. S. Mitchell, M. J. Espy, T. F. Smith, D. R. Toal, P. N. Rys, E. F. Berbari, D. R. Osmon, and D. H. Persing

Journal of Clinical Microbiology, Nov. 1997 p. 2873-2877

Until recently, the laboratory diagnosis of central nervous system (CNS) infections with herpes simplex virus (HSV) has been limited by poor sensitivity and/or specificity. We assessed the diagnostic utility of PCR for detection of HSV in over 2,100 specimens referred to the Mayo Clinic from August 1993 to May 1996...

Branched-chain Fatty Acids: The Case for a Novel Form of Cell-Cell Signalling During Myxococcus Xanthus Development

 

John Downard and Douglas Toal

Molecular Microbiology, 1995: 16(2), 171-175​

Metabolism is a highly regulated process that provides nutrients to cells and essential building blocks for the synthesis of protein, DNA and other macromolecules. In healthy biological systems, metabolism maintains a steady state in which the concentrations of metabolites are relatively constant yet are subject to metabolic demands and environmental stimuli...

The esg Locus of Myxococcus Xanthus Encodes the E1α and E1ß Subunits of a Branched-Chain Keto Acid Dehydrogenase​

Douglas R. Toal, Sandra W. Clifton, Bruce A Roe, John Downard

Molecular Microbiology, 1995: 16(2), 177-189

The esg locus of Myxococcus xanthus appears to control the production of a signal that must be transmitted between cells for the completion of multicellular development DNA sequence analysis suggested that the esg locus encodes the E1 decarboxylase (composed of E1α and E1β subunits) of a branched-chain keto acid dehydrogenase (BCKAD) that is involved in branched-chain amino acid (BCAA) metabolism...

Thank you for reaching out!

AdobeStock_333408301_edited.jpg

This form no longer accepts submissions.